Regulatory sources checked November 7, 2026. General sponsor guidance, not legal advice or an approval guarantee.
If you are comparing a CRO in Guatemala or a CRO en Guatemala, start with the published pathway and with what the firm can document for your protocol. Ministerio de Salud Pública y Asistencia Social (MSPAS), through the Departamento de Regulación y Control de Productos Farmacéuticos y Afines (DRCPFA), is the competent authority under Ministerial Agreement 206-2021. A published framework is not proof that a site is ready or that a CRO already runs studies there.
bioaccess® is based in Miami. This page does not claim a current Guatemala trial, a named hospital, or a local operating team. Ask for a documented, study-specific plan before you commit the country.
What to ask before you hire
- Who files with DRCPFA, and which ethics committee will see the protocol first?
- Is the product a drug Phase I study or a device investigation? Those dossiers are different.
- Which sponsor, CRO or SMO, investigator, monitor, and site registrations does this protocol need, and are the current forms the ones on the MSPAS portal?
- What is the committee’s own meeting calendar? Do not accept a claim of one national committee on a single shared calendar.
- Which documents must be in Spanish, and which may stay in the original language with a Spanish summary?
- How will insurance, investigational import, contracts, and site activation be scheduled? Those steps are not the 30-business-day authority clock.
- Is a commercial registration being mixed into the trial quote?
- Will the file be built so foreign data can be discussed with FDA under 21 CFR 812.28, with eligibility treated as conditional?
What the country page now states
The Guatemala clinical-trial page is the workflow: ethics approval before DRCPFA, form F-EC-a-01 and the related registration forms, the complete-file clock in section 47, and the separate import and insurance steps. It does not claim that Agreement 206-2021 expressly adopts ISO 14155, that every document is bilingual, or that prior foreign approval is the only way a product qualifies.
Section 47 gives DRCPFA up to 30 business days after a complete file, then 15 business days for the applicant to answer a query and 15 business days for a final decision after the required information arrives. That is not an ethics-review target and not a protocol-to-first-patient promise.
Commercial device registration is a different file: Guatemala MSPAS registration and how to register a medical device in Guatemala. Acuerdo Gubernativo 712-99 and Norma Técnica 37 are a commercial framework, not a study permit.
Sibling countries keep their own pages and their own authorities. A Guatemala discussion is not a reason to relabel another country’s regulator, and it is not a claim that one CRO outranks every other firm.
Commercial registration stays separate
bioaccess® can process a manufacturer-funded MSPAS device registration. That offer is not a Guatemala holder subscription, and it is not an investigational authorization. The legal holder, importer, and any transfer follow current MSPAS rules and local counsel. A contract does not override the regulator.
Primary sources
- MSPAS Agreement 206-2021 and the published clinical-trial norm
- Current clinical-trial application and registration forms
- Official ethics committee and CRO/SMO lists
Contact bioaccess® to request a Guatemala feasibility assessment. Bring the product description, development stage, preclinical evidence, proposed population, procedures, and follow-up.
Frequently asked questions
Does this page mean bioaccess® is already running trials in Guatemala?
No. It tells you what to ask, and it points to the published MSPAS pathway. A country commitment still needs a protocol-specific feasibility assessment.
Do Guatemala ethics committees share one calendar?
No. Agreement 206-2021 expects an authorized research ethics committee, and section 38.7 tells each committee to set its own procedures, meeting frequency, and maximum response time. Check the committee’s current authorization and calendar.
Does this page publish a savings or speed percentage?
No. Cost and timing depend on the protocol. No percentage comparison with a U.S. or European program is stated here.